REPLY
1.2.2024 09:31:33 CET | Business Wire | Press release
Solidsoft Reply, a Reply Group company specialising in creating Microsoft Azure cloud-based enterprise solutions, has successfully migrated Finland's National Medicines Verification System to its National Blueprint solution. National Blueprint Solution is Solidsoft Reply's Own National Verification System - A system built on Microsoft Azure cloud technology to verify medicines in accordance to the EU Falsified Medicines Directive (FMD). This notable accomplishment marks a pioneering step for the European Medicines Verification System (EMVS).
Over four years' worth of data, comprising over 500+ million medicines pack records, was meticulously migrated. This complex 10-month project required detailed planning and collaborative engagement with the Finnish Medicines Verification Organisation (FiMVO). It involved the development of a fully validated migration toolset, numerous workshops for Finnish IT suppliers, and documentation on how data is transitioned. This ensured a secure and seamless transition with full traceability of its data for auditing purposes.
David Eccles, Partner at Solidsoft Reply, remarked, “This successful migration is not just a remarkable achievement but also a testament to our engineering expertise and collaborative ethos at Solidsoft Reply. Our partnership with FiMVO was instrumental in overcoming the technical challenges, setting a new standard in the EMVS ecosystem.”
Maija Gohlke General Manager at the Finnish Medicines Verification Organisation FiMVO (Suomen Lääkevarmennus Oy) remarked “the project was handled very professionally and that reflects on the smooth execution of this project, a first of its kind and of a huge magnitude, with so many connection points in the supply chain. The knowledge, dedication and flexibility of the Solidsoft Reply team exceeded our expectations.”
This marks the first-ever migration of a national medicines verification system within the EMVS ecosystem between blueprint providers; and is particularly significant in the context of healthcare and pharmaceuticals, where accuracy, data integrity, and security are paramount. This project is a prime example of Solidsoft Reply’s dedication to enhancing healthcare systems through advanced technology, significantly contributing to the safety and efficacy of healthcare delivery.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
Solidsoft Reply
Solidsoft Reply is the Reply group company creating enterprise strength solutions utilising the Microsoft Azure cloud platform. A global award-winning Microsoft Solutions Partner, Solidsoft Reply is recognised by the Pharmaceutical & Healthcare industries as being one the of leading delivery partners in Verification and Traceability systems world-wide. www.solidsoft.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201923213/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Cessna Caravans to Boost USDA’s Fight Against Crop-Damaging Insects12.5.2026 17:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) has ordered three Cessna Caravan aircraft to support its sterile insect release program protecting citrus crops along the Rio Grande River in southern Texas. The new aircraft are expected to be delivered in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512676348/en/ Mission-Ready: The Cessna Caravan joins USDA’s fight to protect Texas citrus from invasive pests APHIS will use the Caravans to carry and release sterile insects that help prevent the spread of destructive pests, including fruit flies. The environmentally friendly technique helps safeguard fruit-bearing trees, reduce crop damage and protect agricultural industries that rely on healthy harvests. “These aircraft will help APHIS reach remote areas and carry out their important mission o
Elliptic Secures $120 Million Investment From Nasdaq Ventures, Deutsche Bank, One Peak and the British Business Bank12.5.2026 16:05:00 CEST | Press release
The institutions building the future of finance are choosing Elliptic as the standard on-chain analytics for digital assets Elliptic, the global leader in digital asset decisioning, today announced the closing of a $120 million Series D fundraise led by One Peak, with participation from Nasdaq Ventures, Deutsche Bank and the British Business Bank. The round values Elliptic at $670 million. These investors are among the most consequential institutions in global finance, together responsible for trillions in daily market activity, and they have placed their confidence in Elliptic. It is a signal about where the financial system is heading and who is trusted to underpin it, with Elliptic screening more of the global on-chain economy than any other private sector provider. The fundraise will accelerate Elliptic's mission to deliver the enterprise-grade on-chain analytics for the world's largest and most demanding banks, fintechs, government agencies and crypto and payments companies in the
Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure12.5.2026 16:00:00 CEST | Press release
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced the expansion of its development of metrology technologies for next-generation semiconductors, leveraging global research environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512888328/en/ Signing ceremony with imec held on April 9 As part of this initiative, Rigaku is working with imec, a world-leading semiconductor research and innovation hub headquartered in Belgium, under a three-year development program. Through this effort, Rigaku will advance its core X-ray technologies, including 3D device metrology, high-sensitivity detection of ultrathin films and trace elements, and non-destructive inspection of microscopic defects. As semiconductor devices evolve toward advanced architectures such as Gate-All-Around (GAA) and
Aster Guardians Global Nursing Award Announces Top 10 Finalists for 202612.5.2026 15:54:00 CEST | Press release
On the occasion of International Nurses Day, Aster DM Healthcare has announced the Top 10 finalists for the fifth edition of the Aster Guardians Global Nursing Award 2026, selected from over 134,000 registrations across 214* countries and economies. One of the Top 10 finalists will be honoured with the grand title and a prize of USD 250,000. Aster has appointed Ernst & Young LLP as the 'Process Advisors' of the award. EY has defined a three-stage evaluation process to determine the finalists and the winner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512872373/en/ Aster Guardians Global Nursing Awards 2026 - Top 10 Finalists (Photo: AETOSWire) The top 10 finalists for 2026 includes: Dr. Agimol Pradeep (United Kingdom), Dr. Aidah Alkaissi (Sweden), Dinah Sevilla (The Kingdom of Saudi Arabia), Dr. Hammoda Abu-Odah (Hong Kong SAR, China), Hindumbi Kaurom Kakkada (India), Johana Patricia Galvan Barrios (Colombia), Josephin
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress12.5.2026 15:30:00 CEST | Press release
Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts SessionOral and poster presentations to feature new data for INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with myeloproliferative neoplasms (MPNs) Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. “The breadth of the data that will be showcased at the 2026 EHA Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “These presentations include findings fro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
